BlossomHill Therapeutics (NASDAQ:BLSM) Trading Down 5.6% – What’s Next?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)’s stock price traded down 5.6% on Monday . The company traded as low as $18.31 and last traded at $18.46. 36,449 shares were traded during mid-day trading, a decline of 84% from the average session volume of 227,586 shares. The stock had previously closed at $19.56.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th.

BlossomHill Therapeutics Price Performance

Insider Transactions at BlossomHill Therapeutics

In other news, General Counsel Vincent Paul Liptak bought 2,500 shares of the business’s stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $15.80 per share, with a total value of $39,500.00. Following the transaction, the general counsel directly owned 109,212 shares in the company, valued at approximately $1,725,549.60. The trade was a 2.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc purchased 625,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.